Registration for a live webinar on 'Precision medicine treatment for anticancer drug resistance' is now open.
See webinar detailsWe noted you are experiencing viewing problems
-
Check with your IT department that JWPlatform, JWPlayer and Amazon AWS & CloudFront are not being blocked by your network. The relevant domains are *.jwplatform.com, *.jwpsrv.com, *.jwpcdn.com, jwpltx.com, jwpsrv.a.ssl.fastly.net, *.amazonaws.com and *.cloudfront.net. The relevant ports are 80 and 443.
-
Check the following talk links to see which ones work correctly:
Auto Mode
HTTP Progressive Download Send us your results from the above test links at access@hstalks.com and we will contact you with further advice on troubleshooting your viewing problems. -
No luck yet? More tips for troubleshooting viewing issues
-
Contact HST Support access@hstalks.com
-
Please review our troubleshooting guide for tips and advice on resolving your viewing problems.
-
For additional help, please don't hesitate to contact HST support access@hstalks.com
We hope you have enjoyed this limited-length demo
- Research interviews
-
1. The regulation of cell therapy
- Prof. Moutih Rafei
-
2. How and why neurons die in Alzheimer's disease?
- Prof. Bart De Strooper
-
3. The future of blood tests in cancer treatment
- Dr. Isaac Garcia-Murillas
-
4. Role of marketing authorization holder in drug safety
- Dr. Raphael Elmadjian Pareschi
-
5. Synthetic whole embryo models and their applications
- Prof. Jacob (Yaqub) Hanna
-
6. Scale-up challenges in the production of nanomedicines from lab to industry
- Prof. Dr. Oya Tagit
-
7. Artificial intelligence in precision medicine
- Dr. Michael P. Menden
-
8. Translational medicine: the risk of failure in delay and how to reduce it
- Prof. Martin Wehling
-
9. Challenges and solutions of scaling up
- Dr. Shaukat Ali
-
11. Management of generic drug development: challenges and opportunities
- Mr. Sandeep Patil
-
12. MassBank development and future
- Dr. Emma L. Schymanski
-
13. Elite controllers of HIV: from discovery to future therapies
- Prof. Bruce Walker
-
14. Translational research in amyotrophic lateral sclerosis (ALS)
- Prof. Aaron D. Gitler
-
16. PANDAS: a potential link between group A streptococcal infections and neurological disorders
- Prof. P. Patrick Cleary
-
17. Rheumatic diseases and musculoskeletal pain
- Prof. Anisur Rahman
-
18. Towards developing a universal influenza vaccine
- Prof. Peter Palese
- Clinical interviews
-
19. Monkeypox: etiopathogenesis, prevention, and treatments
- Dr. Dennis Hruby
-
20. Kidney xenotransplantation
- Dr. Douglas J. Anderson
-
21. CAR-T and TCR-T cellular immunotherapies in oncology
- Prof. Sebastian Kobold
-
22. MAPS: the business of medical affairs
- Dr. Danie du Plessis
-
23. Hypertrophic cardiomyopathy: therapies and treatments
- Prof. Srihari Naidu
-
24. Combating the HIV epidemic
- Prof. William Blattner
-
25. Epigenetic pharmaceuticals used in the clinic
- Dr. Thomas Paul
-
26. Precision cancer medicine: development and future
- Prof. Maurie Markman
-
27. Pediatric cancer testing
- Prof. Joshua Schiffman
-
28. Opposition to vaccination: a transatlantic discussion
- Prof. Jonathan Temte
-
29. Elective caesarean sections from an evolutionary perspective
- Prof. Wenda Trevathan
-
30. Antiphospholipid syndrome and Lupus
- Prof. Graham Hughes
-
31. Prescribing medications to children - a GP’s view
- Dr. Amanda Simmons
Topics Covered
- Medical Affairs Professional Society (MAPS)
- R&D
- Commercialization
- Strategic leadership
- Pharmaceutical industry
- Funding
- Patient care
- Industry partnership program
- Health equity
- DEI
- ESG
- Affordability
- Ethics
- Professional standards
- Unmet needs
- Patient outcomes
- Real world evidence
- Healthcare system
- Medical affairs profession
Biography
Danie is currently EVP, Medical Affairs at Kyowa Kirin and Chair of the Medical affairs Professional Society (MAPS) board. He is a senior pharmaceutical executive with 30 years’ experience mainly in Medical Affairs. He has a passion for modernising medical affairs and track record in leadership, people development, capability building and coaching. Danie is a qualified MD with a Masters in Clinical Pharmacology who combines medical and life science qualifications with an MBA. Danie has extensive experience building international teams, driving change and working in regulated markets for GlaxoSmithKline (GSK) across Europe, the Americas, Middle East, Africa, Australasia and Japan. He previously worked for Eli Lilly & Company for 17 years in different medical roles as well as marketing and sales. During his different roles, he was based in South Africa, United Kingdom and Australia. Before joining the Pharmaceutical Industry, Danie had his own primary care practice.
Talk Citation
du Plessis, D. (2023, September 28). MAPS: the business of medical affairs [Audio file]. In The Biomedical & Life Sciences Collection, Henry Stewart Talks. Retrieved December 21, 2024, from https://doi.org/10.69645/DQIU1834.Export Citation (RIS)
Publication History
Financial Disclosures
- Dr. Danie du Plessis has not informed HSTalks of any commercial/financial relationship that it is appropriate to disclose.